Location: Las Vegas
Compensation: $60 per visit
Smokers Allowed: Yes
Treatment of hyperlipidemia
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group, multicenter study that will be conducted in North America and Europe. Patients on maximally tolerated background lipid-modifying therapy (LMT) that includes ezetimibe and a maximally tolerated statin that is low dose or less than low dose (including patients unable to tolerate a statin at any dose) and who require additional LDL lowering will be eligible for screening.
The primary objective of this study is to assess the 12-week efficacy of bempedoic acid 180 mg/day versus placebo in decreasing LDL-C when added to ezetimibe therapy in patients with elevated LDL.